Novalis LifeSciences is a venture capital firm focused on early-stage investments in the life sciences industry, particularly at the intersection of bioinformatics and life sciences. Their strategy involves funding capital-light business models and platform technologies that apply innovative information technology to advance disease prevention, diagnosis, or treatment, across sectors like diagnostics, biopharma therapeutics, and life science tools.
Portfolio
4
Fund Size
$500M
Top Stage
Series C
Last 12 Mo
0
Stage Distribution
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| BlueWhale Bio, Inc. | Seed | $18M | Sep 2023 |
| Enko | Series C | $70M | Jul 2022 |
| Ori Biotech Ltd | Series B | $100M | Jan 2022 |
| AgBiome LLC | Series D | $116M | Sep 2021 |
Top Co-Investors
Bill & Melinda Gates Foundation1 shared
Eight Roads Ventures1 shared
Finistere Ventures1 shared
Alumni Ventures Group1 shared
Marshall Wace1 shared
Amadeus Capital Partners1 shared
Northpond Ventures1 shared
Octopus Ventures1 shared
Blue Horizon1 shared
Last updated: 3 March 2026